Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products

This collaboration is a strong strategic and financial fit for Vector,” said William Jackson, CEO of Vector Science & Therapeutics Corp. and CEO of LyoGenesis Plus